ArticleCancer management and research2020
Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Recurrence in Patients with Cervical Cancer.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Role of long non-coding RNA HCG11 in human cancers: From molecular mechanisms to clinical applications (Review).Oncology letters · 2026Review
- Integrative Long Non-Coding RNA Analysis and Recurrence Prediction in Cervical Cancer Using a Recurrent Neural Network.Diagnostics (Basel, Switzerland) · 2025Article
- Integrating Clinical and Transcriptomic Profiles Associated with Vitamin D to Enhance Disease-Free Survival in Cervical Cancer Recurrence Using the CatBoost Algorithm.Diagnostics (Basel, Switzerland) · 2025Article
- Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence.JCO precision oncology · 2025Article
- Upregulation of long non-coding RNA ENSG00000267838 is related to the high risk of progression and non-response to chemoradiotherapy treatment for cervical cancer.Non-coding RNA research · 2025Article
- Bidirectional recurrent neural network approach for predicting cervical cancer recurrence and survival.Scientific reports · 2024Article
- Integrating cat boost algorithm with triangulating feature importance to predict survival outcome in recurrent cervical cancer.Scientific reports · 2024Article
- Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.Biological trace element research · 2024Article
- The joint role of methylation and immune-related lncRNAs in ovarian cancer: Defining molecular subtypes and developing prognostic signature.Translational oncology · 2023Article
- L-RAPiT: A Cloud-Based Computing Pipeline for the Analysis of Long-Read RNA Sequencing Data.International journal of molecular sciences · 2022Article
- Review
- The Role of Long Noncoding RNAs on Male Infertility: A Systematic Review and In Silico Analysis.Biology · 2022Review
- Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas.Scientific reports · 2022Article
- LINC00852 Regulates Cell Proliferation, Invasion, Migration and Apoptosis in Hepatocellular CarcinomaCellular and molecular bioengineering · 2022Article
- Identification of Three Prognosis-Related Differentially Expressed lncRNAs Driven by Copy Number Variation in Thyroid Cancer.Journal of immunology research · 2022Article
- Underexpression ofFrontiers in oncology · 2022Article
- Exploration of potential therapeutic targets for stroke based on the GEO database.Annals of translational medicine · 2021Article
- Selection of Treatment Regimens for Recurrent Cervical Cancer.Frontiers in oncology · 2021Article
- Identification and Analysis of An Epigenetically Regulated Five-lncRNA Signature Associated With Outcome and Chemotherapy Response in Ovarian Cancer.Frontiers in cell and developmental biology · 2021Article
- Long non-coding RNA HCG11 sponging miR-522-3p inhibits the tumorigenesis of non-small cell lung cancer by upregulating SOCS5.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) is one of the most common malignant tumors in women, and its treatment is often accompanied by high recurrence. We aimed to identify the long non-coding RNAs (lncRNAs) associated with CC recurrence.
methodsWe downloaded lncRNAs expression data of CC patients from The Cancer Genome Atlas (TCGA) dataset and used Cox regression models to analyze the lncRNAs relationship with CC recurrence. The significantly associated lncRNAs were utilized to construct a recurrence risk score (RRS) model. Bioinformatics analyses were used to assess the potential role of the critical lncRNAs in CC recurrence. The effect of critical lncRNAs on CC phenotype was determined by in vitro experiments.
resultsUsing Cox regression analysis, four lncRNAs, ie, HCG11, CASC15, LINC00189, and LINC00905, were markedly associated with worse recurrence-free survival (RFS) of CC, whereas three lncRNAs, including HULC, LINC00173, and MIR22HG, were the opposite. After constructing the RRS model, Kaplan-Meier analysis revealed that patients with high RRS had significantly increased risk of recurrence. Among the 20 types of tumors in the TCGA database which all had adjacent normal tissues, MIR22HG and HCG11were significantly downregulated in 18 and 10 types of tumors including CC, respectively. Increased MIR22HG was significantly relevant to decreased risks of recurrence among the subgroups of age at diagnosis < 45 (Hazard Ratio (HR) = 0.26), stage I/II (HR = 0.33), T stage I/II (HR = 0.30), chemotherapy (HR = 0.18), and molecular therapy (HR = 0.16). Functionally, elevated MIR22HG expression could suppress CC cell proliferation, migration and invasion.
conclusionMIR22HG has a fundamental role in CC recurrence and could be served as a potential prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.